• 1
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 3622-3634.
  • 2
    Kirkwood JM, Strawdeman MH, Enstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk respected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 7-17.
  • 3
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 2444-2458.
  • 4
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2 KLH/QS 21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 2370-2380.
  • 5
    Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004; 10: 1670-1677.
  • 6
    Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients, with resected high risk melanoma. J Clin Oncol. 2009; 27: 939-944.
  • 7
    Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29: 241-252.
  • 8
    Wheatley K, Ives N, Eggermont A, et al. Interferon-a as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials [abstract]. Proc Am Soc Clin Oncol 2007; 8526: 478s.
  • 9
    Rubin JT, Day R, Duquesnoy R, et al. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol. 1995; 2: 1-6.
  • 10
    Marincola FM, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with interleukin-2-based immunotherapy. Cancer Res. 1992; 52: 6561-6566.
  • 11
    Scheibenbogen C, Keilholz U, Mytilineos J, et al. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res. 1994; 4: 191-194.
  • 12
    Marincola FM, Shamamian P, Rivoltini L, et al. HLA associations in the antitumor response against malignant melanoma. J Immunother. 1996; 18: 242-252.
  • 13
    Lee J, Reveille JD, Ross MI. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer. 1994; 59: 510-513.
  • 14
    Lee J, Lu M, Mansfield PF, et al. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer. 1996; 78: 758-763.
  • 15
    Lee J, Abdalla J, Porter G, et al. Presence of human leukocyte antigen class II gene DRB1*1101 predicts interferon γ levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2001; 9: 587-593.
  • 16
    Chun YS, Wang JE, Gershenwald MI, et al. HLA class II alleles predict recurrence and pattern of failure in early-stage melanoma patients [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 472s. Abstract 8503.
  • 17
    Klein J, Sato A. The HLA system. Second of 2 parts. N Engl J Med. 2000; 343: 782-786.
  • 18
    Saiki RK, Walsh PS, Levenson et al. Genetic analysis of amplified DNA with immobilized sequence specific oligonucleotide probes. Proc Natl Acad Sci U S A. 1989; 86: 6230-6238.
  • 19
    Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific and rapid technique. Tissue Antigens. 1991; 37: 197-204.
  • 20
    Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2002. Hum Immunol. 2002; 63: 1213-1268.
  • 21
    Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354: 709-718.
  • 22
    Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
  • 23
    Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens. 1994; 43: 18-27.
  • 24
    Luongo V, Pirozzi G, Caraco C, et al. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens. 2004; 64: 84-87.
  • 25
    Nagore E, Planelles MD, Ledesma E, et al. Molecular genetic analysis of HLA-DR and -DQ alleles in Spanish patients with melanoma. Acta Derm Venereol. 2002; 82: 90-93.
  • 26
    Ryder LP, Andersen E, Svejgaard A. An HLA map of Europe. Hum Hered. 1978; 28: 171-200.
  • 27
    Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002; 95: 1101-1112.
  • 28
    Altmann DM, Sansom D, Marsh SGE. What is the basis for HLA-DQ associations with autoimmune disease? Immunol Today. 1991; 12: 267-270.
  • 29
    Hoon DSB, Okamoto T, Wang HJ, et al. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol. 1998; 16: 1430-1437.
  • 30
    Muixi L, Alvarez I, Jaraquemada D. Peptides presented in vivo by HLA-DR in thyroid autoimmunity. Adv Immunol. 2008; 99: 165-209.
  • 31
    Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon alpha2b. Clin Cancer Res. 2007; 13: 2422-2428.